NASDAQ:ATRC AtriCure Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AtriCure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $39.99 +0.10 (+0.25 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$39.59Now: $39.99▼$41.2350-Day Range$39.89MA: $41.73▼$44.8952-Week Range$23.17Now: $39.99▼$51.76Volume782,641 shsAverage Volume415,230 shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/ABeta0.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.71, AtriCure has a forecasted upside of 31.8% from its current price of $39.99.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAtriCure has received 485 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtriCure has received 356 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtriCure has received 57.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote “Outperform” if you believe ATRC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $442,473.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of AtriCure is held by insiders.Percentage Held by Institutions93.50% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($1.30) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -31.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -31.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 6.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC Previous Symbol CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone513-755-4100Debt Debt-to-Equity Ratio0.16 Current Ratio7.67 Quick Ratio6.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$230.81 million Price / Sales7.78 Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book6.40Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-35,190,000.00 Net Margins-23.64% Return on Equity-19.55% Return on Assets-9.56%Miscellaneous Employees620 Outstanding Shares44,932,000Market Cap$1.80 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $39.99 +0.10 (+0.25 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATRC News and Ratings via Email Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. AtriCure (NASDAQ:ATRC) Frequently Asked Questions How has AtriCure's stock been impacted by Coronavirus (COVID-19)? AtriCure's stock was trading at $35.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATRC stock has increased by 13.4% and is now trading at $39.99. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of AtriCure? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AtriCure. When is AtriCure's next earnings date? AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for AtriCure. How were AtriCure's earnings last quarter? AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Tuesday, July, 28th. The medical device company reported ($0.38) EPS for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.21. The medical device company had revenue of $40.82 million for the quarter, compared to the consensus estimate of $36.07 million. AtriCure had a negative net margin of 23.64% and a negative return on equity of 19.55%. The company's revenue for the quarter was down 30.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) earnings per share. View AtriCure's earnings history. What price target have analysts set for ATRC? 7 brokerages have issued twelve-month price targets for AtriCure's stock. Their forecasts range from $45.00 to $60.00. On average, they expect AtriCure's share price to reach $52.71 in the next year. This suggests a possible upside of 31.8% from the stock's current price. View analysts' price targets for AtriCure. Are investors shorting AtriCure? AtriCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,070,000 shares, an increase of 15.0% from the August 15th total of 1,800,000 shares. Based on an average trading volume of 314,200 shares, the short-interest ratio is currently 6.6 days. View AtriCure's Short Interest. Who are some of AtriCure's key competitors? Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR) and Steris (STE). View all competitors. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Alnylam Pharmaceuticals (ALNY) and Chevron (CVX). Who are AtriCure's key executives? AtriCure's management team includes the following people: Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)Mr. Douglas J. Seith, Chief Operating Officer (Age 53)Mr. Salvatore Privitera, Chief Technology Officer (Age 52)Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41) What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." Who are AtriCure's major shareholders? AtriCure's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (10.61%), Vanguard Group Inc. (5.05%), Orbimed Advisors LLC (2.73%), TimesSquare Capital Management LLC (2.62%), Gilder Gagnon Howe & Co. LLC (2.30%) and GW&K Investment Management LLC (1.92%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View institutional ownership trends for AtriCure. Which institutional investors are selling AtriCure stock? ATRC stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, GW&K Investment Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Neuberger Berman Group LLC, Peregrine Capital Management LLC, Silvercrest Asset Management Group LLC, Nuveen Asset Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel, and Regina E Groves. View insider buying and selling activity for AtriCure. Which institutional investors are buying AtriCure stock? ATRC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, TimesSquare Capital Management LLC, Gilder Gagnon Howe & Co. LLC, Orbimed Advisors LLC, Perceptive Advisors LLC, Vanguard Group Inc., Man Group plc, and Driehaus Capital Management LLC. View insider buying and selling activity for AtriCure. How do I buy shares of AtriCure? Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $39.99. How big of a company is AtriCure? AtriCure has a market capitalization of $1.80 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe. What is AtriCure's official website? The official website for AtriCure is www.atricure.com. How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100. This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
